This CME/CNE activity will include clinical updates for the treatment of Multiple Myeloma with reduced bone complications. Expert faculty will review the science of multiple myeloma, including disease course, patient assessment and comorbidities. The current head to head trial data for emerging therapeutics for the treatment of relapsed/refractory multiple myeloma will be analyzed. The faculty will guide clinicians on how to incorporate optimal treatment strategies into patient-specific plans to improve the overall survival in patients with multiple myeloma with reduced bone complications. Upon completing this activity, clinicians will gain knowledge on the most up-to-date care for this cohort of patients.
Hematologists/Oncologists, primary care physicians, nurse practitioners, and other healthcare professionals responsible for the treatment of Multiple Myeloma.
1. Identify the science of multiple myeloma, including disease course, patient assessment and comorbidities.
2. Analyze the current head to head trial data for emerging therapeutics for the treatment of relapsed/refractory multiple myeloma.
3. Incorporate optimal treatment strategies into patient-specific plans to improve the overall survival in patients with multiple myeloma with reduced bone complications.
Beth Faiman PhD, MSN, APN-BC, AOCN
Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute
Ruben Niesvizky, MD
Professor of Medicine
Weill Cornell Medical College
Director, Multiple Myeloma Center and Oncology Operations
New York Presbyterian Hospital/Weill Cornell Medicine
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
|Faculty||Relationship Identified With:|
|C. Ola Landgren, MD, PhD||Consultant/Advisor: Amgen Inc.; Merck & Co. Pharmaceutical Company; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.|
|Beth Faiman PhD, MSN, APN-BC, AOCN
|Consultant/Advisor: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceuticals U.S.A., Inc.
Speaker’s Bureau: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceuticals U.S.A., Inc.
|Ruben Niesvizky, MD||Speaker’s Bureau: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Global Services, LLC; Takeda Pharmaceuticals U.S.A., Inc.
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME/CNE Inquiries/Special Needs
Provided by AcademicCME.